22157.jpg
Digital Health for Obesity: A $457.4 Billion Global Market by 2034 - Uncover the Segments and Countries Projected to Experience the Fastest Growth, Along with Profiles of the Leading Players
July 01, 2024 09:25 ET | Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Global Digital Health for Obesity Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
22157.jpg
Anti-obesity Medication Market Analysis 2024-2034 by Product, Mechanism of Action, Distribution Channel and Region - Global Industry Projected to Register 31.71% CAGR, Reaching $137.4 Billion by 2034
June 26, 2024 06:55 ET | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market" report has been added to ResearchAndMarkets.com's offering.The global anti-obesity medication market accounted...
Fractyl-Logo.png
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
June 25, 2024 07:00 ET | Fractyl Health, Inc.
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Cardiometabolic Heal
Cardiometabolic Health Congress (CMHC) will present the results of a webcast series designed to help practitioners improve patient care
June 24, 2024 10:48 ET | Cardiometabolic Health Congress
Boca Raton, FL, June 24, 2024 (GLOBE NEWSWIRE) -- The ADA 2024 Scientific Sessions center on the latest cutting-edge advances in diabetes research, prevention, and care. The event will be held June...
Rani-Logo.jpg
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
June 24, 2024 07:00 ET | Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...
Fractyl-Logo.png
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
June 24, 2024 06:00 ET | Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
zealand_logo_RGB_01.png
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024 11:37 ET | Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
800 px horizontal logo.png
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024 09:00 ET | Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
Logo Resized for Globe Newswire2.jpg
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET | Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...